



AGM OVERVIEW 2019

Prescient Therapeutics Limited (ASX: PTX)

19 November 2019

Disclaimer and safe harbor

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited ("Prescient" or the "Company"), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words 'estimate', 'project', 'intend', 'expect', 'plan', 'believe', 'guidance', and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management's current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. In particular, there are substantial risks in drug development including risks that studies fail to achieve an acceptable level of safety and/or efficacy. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Prescient only as of the date of this presentation. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words "believes," "plans," "expects," "anticipates," and words of similar import, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favorable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.

A (busy) year in review

- A successful **A\$9 million capital raising** supported by existing shareholders and several leading US and Australian specialist life science investors.
- **Clinical progress** in the HER2 negative breast cancer, relapsed and refractory acute myeloid leukemia and recurrent or platinum resistant ovarian cancer trials.
- **Expansion of the AML trial** to explore the potential of PTX-200 in lower doses of chemotherapy based on the strong data from the Phase 1b study and endorsement of medical investigators.
- Positive interim durability data from the HER2 negative breast cancer study showed all five responders saw **no disease progression after two years**.
- Collaboration with a private US-based company to create **new formulations** of our lead compound and significantly expand our robust intellectual property.
- Developing of a **higher yielding and lower-cost manufacturing route** for PTX-100 to address significant technical challenges related to manufacturing.
- Manufacturing **additional supply of PTX-200** to address clinical trial demand.
- Significant preparation to plan and then initiate a **novel “basket” PK/PD study of PTX-100** in hard to treat cancers with high unmet needs.
- **Active business development** to promote awareness of our programs to third parties, and identify value-adding opportunities for Prescient.
- Collaboration to extend targeted therapies into exciting **CAR-T applications**

Once again tracking against prior year's objectives.

Last year we said:

- Initiate the PTX-100 PK/PD study ✓
- Complete Phase 2 (part1) of PTX-200 in breast cancer ON TRACK FOR Q4
- Complete Phase 1b expanded cohort of PTX-200 in AML ON TRACK FOR Q4
- Complete Phase 1b PTX-200 in Ovarian cancer ON TRACK FOR Q4
- Undertake manufacturing run of PTX-100 and additional inventory of PTX-200 ✓
- Collaboration on next generation formulations of PH domain/Akt inhibitors ✓
- Ongoing business development activities ✓
- Continue to build awareness among investors, clinicians and corporates ✓

Overcoming inevitable challenges

inherent in drug development, including:

- Increasing headwinds with falling AUD:USD exchange rate



- Prescient remains within budget, but it will be prudent to either migrate some US trials to Australia, and/or seek investigator sponsored initiatives and grants

- Optimising combinations with PTX-200



- Protocol amendments to optimise therapeutic effect, whilst minimising drug:drug interactions

- Unprecedented PTX-100 basket trial protocol design for both solid and haematological cancers



- Completed with input from great clinical and scientific team and highly experienced investigators

- Manufacturing challenges with PTX-100



- Developed a more efficient manufacturing process for PTX-100
- Working with manufacturer to on process improvement for future manufacturing

Working in areas of significant business development interest

...and it's not just us saying so:

SACHS ASSOCIATES, 19TH ANNUAL BIOTECH IN EUROPE FORUM
SESSION ON ONCOLOGY BUSINESS DEVELOPMENT

Trends in Oncology Business Development

September 26, 2019

Targeted Therapies:

“Targeted therapeutic business development activity is exceptional...

This area will stay hot but there has to be a targeted population to identify with a clear benefit.”

Drugging the Undruggable:

“Drugging the undruggable is another top strategic theme. Amgen's recent KRAS data are stunning. We expect a surge in business development activity in this area...”

Landscape continues to move in our favour

- 2019 saw several major industry developments in targeted therapies, validating our investment and strategy.
- There is no sign this industry trend will slow down.
- Like these companies, Prescient's targeted therapies target mutations that drive a wide variety of tumor types.



US\$5.1B buyout
by GSK
Dec 2018



GlaxoSmithKline



US\$8B buyout
by Eli Lilly
Jan 2019



US\$11.4B buyout
by Pfizer
June 2019



Ras mutations dominating industry headlines

Vantage June 04, 2019

Asco 2019 – KRAS chase heats up with Amgen data



Madeleine Armstrong



Amgen has gone further than anyone before to crack KRAS, but caution is required, as efficacy might ultimately not be as positive as initial data suggest.

Early cancer drug data give Amgen hope it has 'cracked KRAS code'

BRIEF

Amgen's KRAS success has other drugmakers eager to follow

Biotech

Mirati sets date for closely watched clinical KRAS readout

by Nick Paul Taylor | Oct 18, 2019 8:28am

Mirati data to test whether biotech can challenge Amgen in KRAS quest

ONCOLOGY

Notorious KRAS: Taking down cancer researchers' biggest foe

After decades of failures, the first wave of KRAS G12C inhibitors has reached the clinic. Can the feat be repeated with other RAS proteins?

by Lisa M. Jarvis

Mirati clears first clinical hurdle in KRAS race against Amgen

by Nick Paul Taylor | Oct 29, 2019 3:42am

Shares in Mirati climbed 14% in after-hours trading, adding to a valuation that had already topped \$3 billion on excitement about the potential of finally drugging KRAS. Amgen finished the day up by 1%.

Business

Amgen's 'White Whale' Cancer Data May Send Shares to Record High




By [Cristin Flanagan](#)

4 September 2019, 23:15 GMT+10


Watch out, Amgen and Mirati. Boehringer's pan-KRAS inhibitor enters cancer clinical trials

by [Angus Liu](#) | Oct 30, 2019 8:42am

— Listed Ras peers


				
Drug	AMG-510	MRTX849	G12Di	PTX-100
Inhibits	KRAS G12C	KRAS G12C	KRAS G12D	K-Ras N-Ras RhoA
Phase	Phase 1	Phase 1	Preclinical	Phase 1b
Market cap	US \$121 B	US\$3 B		A\$24 M

Personalised Medicine Strategy: Targeted Therapies and beyond




What is CAR-T therapy?

- **Chimeric Antigen Receptor T-cell therapy**
 - the most *personalised* medicine!
- Genetically modifying a patient's own T-cells (a type of white blood cell that fights infection) by adding a new receptor ("CAR")
- Enables the new T-cell to recognise and attack cancer cells, resulting in cancer cell death
- Stunning responses in certain blood cancers (B cell malignancies)
- Industry trying to overcome challenges to replicate CAR-T success into other types of cancer
 - **This is a big area of opportunity!**



Targeted therapy/CAR-T therapy collaboration


- Collaboration with private CAR-T company Carina Biotech
- Seeking to address some of the current challenges of CAR-T therapy
- Combines Prescient's knowledge of targeted therapies with Carina's cell therapies to improve CAR-T approaches
- Prescient and Carina will share any resulting intellectual property from the collaboration



Presentation summary

ASX CODE: PTX

- Another year of solid progress
- PTX-200 in 3 studies; results out shortly
- PTX-100 trial underway & uniquely positioned in hot Ras space
- Both drugs have potential advantages over competitors' approaches
- **Personalised medicine approach: Extending beyond targeted therapies into CAR-T applications**
- Funding in place



Contact US

 Steven Yatomi-Clarke
CEO & Managing Director

 steven@ptxtherapeutics.com

 +61 417 601 440

 ptxtherapeutics.com